Bristol Myers Squibb
MSD Sharp & Dohme
Recordati Rare Diseases Germany
According to the specifications of the FSA (Voluntary Self-Regulation for the Drug Industry eV), the conditions and the extent of the support of member companies should be presented to the participants in a transparent manner both in the congress announcement and in the implementation.
According to the guidelines of the AKG (Medicines and Cooperation in Health Care e. The publication of the type and scope of the overall support does not represent an obligation for the AKG member companies and is done here voluntarily after written consent.
Should disclosure of all paid exhibition or sponsorship sums be necessary for a CME certification of the congress by the responsible state medical association, INTERPLAN reserves the right to comply. Only the company name and amount are disclosed. Personal data will not be passed on under any circumstances.